Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More